Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In this study a venous blood specimen was drawn and, at the same time, rubella vaccine was given to 1906 schoolgirls mostly in the pre-pubertal age. To assess the pre-vaccination immune status and the effect of the vaccine, a second blood sample was taken 6 weeks later and tested for rubella HAI antibody simultaneously with the first one. RA 27/3 rubella vaccine administered by intranasal route to 81 girls produced a 100% seroconversion rate and the same vaccine strain, given by subcutaneous route to 460 girls, produced a 94.73% seroconversion rate. Among the 1, 365 schoolgirls who received subcutaneous Cendehill vaccine, the seroconversion rate was 86.68%. Side effects were mild and transient and occurred, as headache, most frequently among the girls who received RA 27/3 vaccine by intranasal route.
 ...
PMID:Intranasal versus subcutaneous rubella vaccination in schoolgirls. 95 70

This study of 724 13-year-old schoolgirls in the County Borough of Reading showed that approximately 25% were susceptible to rubella. 96.1% of the 129 seronegative girls and significant numbers of girls with low rubella HAI antibody titres responded to subcutaneous vaccination with Wistar RA. 27/3 rubella vaccine. The incidence of most reactions after vaccination was similar in those who responded to vaccine and those who were initially immune but did not develop rising antibody titres, but rash, lymphadenopathy and headache occurred significantly more frequently in the susceptible group.
 ...
PMID:Vaccination against rubella of susceptible schoolgirls in Reading. 425 64

The serologic responses and the side effects resulting from the administration of a new subunit vaccine against influenza were compared with those of a currently available whole-virus vaccine in an elderly population. The subunit vaccine is prepared by cleavage of the hemagglutinin and neuraminidase surface antigens from the virus with a cationic detergent, cetyltrimethylammonium bromide. The resulting vaccine is more selectively reduced to these primary antigens than are the available subunit vaccines produced by the use of lipid solvents that disrupt the viral membrane [1]. Previous studies in younger individuals with new subunit preparations of earlier H3N2-subtype viruses as well as influenza A/New Jersey/76 (HswN1) and B/Hong Kong/73 viruses indicated that antibody responses in primed, although not in unprimed, populations wee comparable to those induced by whole-virus vaccines and that side effects were few [2,3]. There were not statistically significant differences in the serologic responses of the vaccine recipients except that the percentage of recipients who achieved titers of HAI antibodies of 1:10 or 1:20 to influenza B/Singapore/222/70 virus after vaccination was greater in the subjects who received the subunit vaccine. There were no statistically significant differences in the percentage of recipients with an antibody response (fourfold or greater in titer) or in the geometric mean titers of HAI antibodies after vaccination between those who had received the trivalent influenza virus vaccine in 1979 and those who had no history of vaccination in 1979. Mild redness and/or tenderness were noticed at the injection site between 6 and 48 hr after vaccination in 16 subjects who received the subunit vaccine and in four subjects who received the subunit vaccine and two who received the whole-virus vaccine (P less than 0.01 by chi 2 test). One patient in each group complained of headache; four subjects who received the subunit vaccine and two who received the whole-virus vaccine complained of fatigue.
 ...
PMID:Responses of elderly subjects to a new subunit influenza virus vaccine. 705 32

We studied the safety and immunogenicity of a nasally administered vaccine comprising three monovalent inactivated influenza antigens (A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Guangdong/120/2000) non-covalently associated with outer membrane proteins of Neisseria meningitidis (Proteosome) in normal, healthy adults. In a randomized, double-blind trial participants (n = 78) were allocated to placebo or a single nasal dose of vaccine containing 15, 30, or 45 microg of each of the three HA antigens, or two nasal doses containing 30 microg of each HA, separated by 2 weeks. The vaccine was generally well tolerated in all doses tested, and in a one or two-dose schedule. A shallow vaccine reactogenicity dose-response was seen. The most common local reaction was nasal congestion, which occurred in up to 48.3% of vaccine recipients in days 0-6 after vaccine but was mild and self-limiting; this reaction was not significantly more common among active vaccine recipients than placebo recipients. Mild to moderate headache was the most commonly reported systemic reactogenicity complaint in all treatment groups, and was the only solicited complaint to increase significantly in frequency after a second active dose. No severe systemic reactions occurred. A positive and statistically significant antibody response was observed, in serum and in nasal secretions, to increasing dose for all three antigens. Serum HAI titre responses and nasal secretory IgA immune responses were elicited against all three antigens. Further testing of this nasal influenza vaccine is warranted to determine its safety and immunogenicity in these populations and its efficacy in the prevention of clinical illness.
 ...
PMID:Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults. 1630 15